ANALYSIS OF CLINICAL-TRIALS BY TREATMENT ACTUALLY RECEIVED - IS IT REALLY AN OPTION

被引:213
作者
LEE, YJ
ELLENBERG, JH
HIRTZ, DG
NELSON, KB
机构
[1] National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, 20892, 7550 Wisconsin Avenue, Federal Building
关键词
D O I
10.1002/sim.4780101011
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The primary analysis of a randomized clinical trial should compare patients in their randomly assigned treatment groups (intention to treat analysis). When a substantial number of subjects fail to take a prescribed medication or are switched to a different study medication, it is tempting to consider treatment comparisons using only those subjects with treatment as actually received rather than as prescribed. There are several arguments against this approach: the prognostic balance brought about by randomization is likely to be disturbed; sample size will be reduced; and the validity of the statistical test procedures will be undermined. Further, results of analysis by treatment actually received may suffer from a bias introduced by using compliance, a factor often related to outcome independently of the treatment received, to determine the groups for comparison. The extent and nature of this bias will be related to the definition of compliance in an as treated analysis, a definition which could be unintentionally self-serving. We have investigated the problem of the definition of actual treatment in the context of a recent clinical trial. We used several definitions to classify patients as having received or not received treatment as prescribed. These definitions, when used in as treated analyses, provided results that were at times inconsistent or counter-intuitive, and which neither helped to confirm nor further explain the intention to treat analysis.
引用
收藏
页码:1595 / 1605
页数:11
相关论文
共 21 条
  • [1] Canner P.L., Monitoring clinical trial data for evidence of adverse or beneficial treatment effects, INSERM, 76, pp. 131-149, (1977)
  • [2] Friedman L.M., Furberg C.D., DeMets D.L., Fundamentals of Clinical Trials, (1985)
  • [3] Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., Smith P.G., Design and analysis of randomized clinical trials requiring prolonged observation of each patient, British Journal of Cancer, 34, pp. 585-612, (1976)
  • [4] Meinert C.L., Clinical Trials—Design, Conduct, and Analysis, (1986)
  • [5] Pocock S.J., Clinical Trials: A Practical Approach, (1983)
  • [6] Ellenberg J.H., Presidential address: biostatistical collaboration in medical research, Biometrics, 46, pp. 1-29, (1990)
  • [7] Schwartz D., Lellouch J., Explanatory and pragmatic attitudes in therapeutic trials, Journal of Chronic Diseases, 20, pp. 637-648, (1967)
  • [8] Armitage P., The analysis of data from clinical trials, The Statistician, 28, pp. 171-183, (1979)
  • [9] Detre K., Peduzzi P., The problem of attributing deaths of non‐adherers: the VA Coronary Bypass experience, Controlled Clinical Trials, 3, pp. 355-364, (1982)
  • [10] Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project, New England Journal of Medicine, 303, pp. 1038-1041, (1980)